P1396: CD33-DELETED HEMATOPOIETIC STEM AND PROGENITOR CELLS DISPLAY NORMAL ENGRAFTMENT AFTER HEMATOPOIETIC CELL TRANSPLANT (HCT) AND TOLERATE POST-HCT GEMTUZUMAB OZOGAMICIN (GO) WITHOUT CYTOPENIAS
Guenther Koehne(Baptist Hospital of Miami), Christina Cho(Albany Medical Center Hospital), Divya Koura(University of California San Diego), Nirali N. Shah(National Institutes of Health), Hyung C. Suh(Science Applications International Corporation (United States)), Glen Raffel(University of Massachusetts Chan Medical School), Kyle Breitschwerdt, Nadia M. Bambace(Hôpital Maisonneuve-Rosemont), Michael R. Loken(Unknown), John F. DiPersio(Washington University in St. Louis), Sritama Nath(University of North Carolina at Charlotte), Miguel‐Angel Perales(Memorial Sloan Kettering Cancer Center), Benjamin Tomlinson(University Hospitals Cleveland Medical Center), Roland B. Walter(Rafael Advanced Defense Systems (Israel)), Léa Bernard(Hôpital Maisonneuve-Rosemont)
Cited by 3
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2018|1k
Three-dimensional culture systems in cancer research: Focus on tumor spheroid model
|Pharmacology & Therapeutics|2016|921
Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse
|Journal of Clinical Oncology|2001|898